Excerpt of coverage from GEN:
“Under the BARDA contract, Cerus will receive initial funding of up to $30,750,939 to support activities related to a clinical trial to assess the safety and efficacy of Intercept RBCs compared to conventional RBCs in Puerto Rico, which has been impacted by the Zika virus epidemic. This funding also will support activities related to in vitro studies to facilitate potential pivotal Phase III clinical trials in the continental U.S.
In addition to the base period where BARDA has committed the initial funding, the five-year contract includes option periods that, if exercised by BARDA and completed, would bring the total non-dilutive funding opportunity to up to $180,509,914. The subsequent options would fund activities related to broader implementation in areas of Zika virus risk, clinical and regulatory development programs in support of licensing, and development, manufacturing and scale-up activities.”